Want to see AU:ZNO full AI Analyst Report?
Top Page
Zoono Group Limited
(Sydney:ZNO)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.06
▼(-28.75% Downside)
Action:Reiterated
Date:06/25/26
The score is driven primarily by weak financial performance, with persistent losses, negative margins, and ongoing cash burn outweighing the benefit of low leverage. Technicals also detract as the stock trades below major moving averages with negative MACD, while valuation is difficult to justify due to loss-making earnings (negative P/E) and no indicated dividend yield.
Positive Factors
Long‑lasting antimicrobial product differentiation
Zoono's core product claim—long‑lasting antimicrobial protection—supports premium positioning and repeat purchase potential across consumer and commercial channels. Structurally, durable efficacy claims can sustain B2B contracts and retail loyalty, aiding revenue stability over months as distribution scales.
Negative Factors
Persistent negative cash generation
Sustained operating cash outflows mean the business cannot internally fund working capital or growth, increasing reliance on external financing and raising dilution risk. Over the coming months, weak cash generation constrains marketing, inventory, and distribution investments needed to convert demand into durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Long‑lasting antimicrobial product differentiation
Zoono's core product claim—long‑lasting antimicrobial protection—supports premium positioning and repeat purchase potential across consumer and commercial channels. Structurally, durable efficacy claims can sustain B2B contracts and retail loyalty, aiding revenue stability over months as distribution scales.
Read all positive factors
Zoono Group Limited (ZNO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$24.37M
Dividend YieldN/A
Average Volume (3M)153.26K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth-7.01%
EPS Growth26.92%
CountryAU
Employees2
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding406,211,760
10 Day Avg. Volume257,173
30 Day Avg. Volume153,260
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.62
Price to Sales (P/S)9.30
P/FCF Ratio-6.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zoono Group Limited Business Overview & Revenue Model
Company Description
Zoono Group Limited, along with its associated entities, specializes in the innovation, development, and global distribution of a variety of antimicrobial solutions, catering to both the New Zealand market and international clientele. Their produc...
How the Company Makes Money
Zoono primarily makes money by selling antimicrobial and sanitising products (including surface sanitiser and hand sanitiser formats) under its brand, generating revenue when these products are ordered by commercial customers and distributed into ...
Zoono Group Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 950.69K | 1.16M | 960.30K | 3.07M | 8.13M | 25.22M |
| Gross Profit | -709.17K | -281.53K | -4.36M | -625.33K | 2.10M | 11.88M |
| EBITDA | -3.07M | -3.26M | -7.89M | -181.62K | -5.11M | 5.89M |
| Net Income | -3.51M | -3.64M | -8.30M | -321.97K | -10.28M | 4.40M |
Balance Sheet | ||||||
| Total Assets | 6.01M | 5.87M | 9.01M | 13.40M | 17.68M | 29.46M |
| Cash, Cash Equivalents and Short-Term Investments | 475.33K | 47.30K | 1.79M | 759.99K | 3.30M | 4.55M |
| Total Debt | 625.70K | 544.56K | 726.63K | 868.99K | 1.00M | 1.93M |
| Total Liabilities | 2.53M | 2.89M | 2.76M | 3.24M | 8.41M | 9.88M |
| Stockholders Equity | 3.47M | 2.97M | 6.24M | 10.16M | 10.00M | 19.68M |
Cash Flow | ||||||
| Free Cash Flow | -1.76M | -1.58M | -2.89M | -3.55M | -996.61K | 834.07K |
| Operating Cash Flow | -1.76M | -1.58M | -2.89M | -3.55M | -974.11K | 1.38M |
| Investing Cash Flow | 0.00 | 0.00 | -58.73K | -53.49K | -107.62K | -1.26M |
| Financing Cash Flow | 1.50M | -190.15K | 3.99M | 873.62K | -54.99K | -4.82M |
Zoono Group Limited Technical Analysis
Negative
0.08
Price Trends
0.06
Negative
0.06
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
36.48
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZNO, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.48 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ZNO.
Zoono Group Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | AU$20.15M | -1.11 | -22.89% | ― | 19.92% | 11.14% | |
45 Neutral | AU$4.09M | -3.65 | -10.69% | ― | -23.30% | 78.42% | |
45 Neutral | AU$19.00M | -1.36 | 2542.90% | ― | -47.12% | -18.92% | |
41 Neutral | AU$24.37M | -5.74 | -108.90% | ― | -7.01% | 26.92% | |
40 Underperform | AU$5.99M | -1.95 | -44.35% | ― | -32.09% | 34.85% |
* Consumer Defensive Sector Average
AU:ZNO
Zoono Group Limited
0.05
0.02
74.19%
AU:PTL
Pental Ltd.
0.02
-0.04
-60.34%
AU:MCP
Mcpherson'S Limited
0.14
-0.15
-51.72%
AU:EVE
EVE Health Group Limited
0.02
-0.01
-43.33%
AU:SKN
Skin Elements Limited
―
―
―
Zoono Group Limited Corporate Events
Zoono Secures First Major UK Soft-Fruit Packaging Orders as Global Rollout Builds
May 27, 2026
Zoono Group Limited and its hygiene-technology partner OSY Group have secured their first material commercial orders from Sharpak Aylesham in the U.K. soft fruits packaging market, under an exclusive contract granting Sharpak rights to use Zoono&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.